Congo launches Ebola vaccination drive to tackle deadly outbreak

The Democratic Republic of Congo (DRC) has begun a national Ebola vaccination campaign in response to the country’s most severe outbreak of the disease to date. Health authorities announced that the campaign will use a vaccine originally developed for the Zaire strain of Ebola, as no vaccine is yet available for the Bundibugyo variant that is circulating in the affected regions.

The Bundibugyo outbreak, first detected in 2023 in the eastern provinces of North Kivu and Ituri, has already reported more than 600 confirmed cases and 250 deaths, according to the DRC Ministry of Health. The outbreak’s fatality rate, estimated at around 40 percent, is higher than the average for Ebola and has prompted an urgent response from both national and international partners. The World Health Organization (WHO) has declared the outbreak a public health emergency of international concern, citing its rapid spread and the limited capacity of local health systems.

The rVSV-ZEBOV vaccine, which has been used successfully in previous Zaire strain outbreaks, is being deployed through a ring‑vaccination strategy. In this approach, contacts of confirmed cases and individuals at high risk of exposure are identified and vaccinated within a 10‑kilometer radius of the patient’s location. The campaign will prioritize health workers, caregivers, and household members of patients, as well as community leaders who can help facilitate acceptance. Each vaccinated individual receives a single dose, and the vaccine’s protective effect is expected to develop within 10 days.

Because the Bundibugyo strain differs genetically from the Zaire strain, the use of the rVSV-ZEBOV vaccine is a stop‑gap measure. Clinical studies have shown that the vaccine offers cross‑protection against several Ebola subtypes, but efficacy against Bundibugyo is not yet fully established. Nevertheless, health officials argue that any level of protection is preferable to no intervention, especially given the high mortality rate and the speed at which the virus is spreading.

Logistically, the campaign will rely on a network of regional health centers, mobile clinics, and community volunteers to deliver vaccines and monitor for side effects. Cold‑chain equipment, donated by the Global Alliance for Vaccines and Immunisation (GAVI), will support vaccine storage in remote villages. The DRC’s Ministry of Health has pledged to train 1,200 health workers over the next month to administer the vaccine and conduct contact tracing.

Security concerns remain a significant hurdle. Armed groups in eastern DRC have disrupted health services in the past, and there have been reports of violence against health workers. To mitigate these risks, the campaign will coordinate with local police and the United Nations peacekeeping mission (MONUSCO) to ensure safe passage for medical teams. Community outreach efforts aim to address vaccine hesitancy and misinformation, which have been identified as barriers to acceptance in previous outbreaks.

International partners are providing substantial support. WHO is supplying technical guidance and monitoring tools, while UNICEF is assisting with logistics and community engagement. Médecins Sans Frontières (MSF) has deployed teams to support surveillance and treatment centers. Funding from the Global Fund and the United Nations Development Programme (UNDP) will cover vaccine procurement, staff salaries, and protective equipment.

The DRC’s experience with Ebola is extensive. The 2018‑2020 outbreak, which claimed 2,300 lives, was the largest in the country’s history. The current outbreak, however, has surpassed previous ones in both scale and speed of transmission. Analysts note that the rapid deployment of a vaccine, even one designed for a different strain, could significantly reduce the number of new infections and prevent further spread into neighboring countries.

While the vaccination campaign represents a critical step, experts emphasize that it is not a permanent solution. Continued surveillance, rapid diagnostic testing, and treatment of patients remain essential. Additionally, the development of a dedicated vaccine for the Bundibugyo variant is a priority for researchers and vaccine manufacturers. In the meantime, the DRC’s combined strategy of vaccination, contact tracing, and community education seeks to curb the outbreak and protect the most vulnerable populations.